Clinical trials: Moderate-to-severe Atopic Dermatitis
Moderate to Severe Atopic Dermatitis
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
- Trial name
- NCT05549947
- Testing
- SHR-1819
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Moderate-to-severe Atopic Dermatitis
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07211542
- Testing
- SHR-1905 Injection, SHR-1905 Injection Blank Preparation
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate-to-Severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07502222
- Testing
- AK139
- Volunteers
- 168 people
- Sponsor
- Akeso
Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy, safety, and tolerability of CMS-D001 in participants with moderate to severe atopic dermatitis…
- Trial name
- NCT07465120
- Testing
- CMS-D001 50mg, CMS-D001 100mg, CMS-D001 200mg
- Where
- 28 sites in China
- Volunteers
- 160 people
- Sponsor
- Dermavon Holdings Limited
Moderate to Severe Atopic Dermatitis
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of SHR-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously…
- Trial name
- NCT06012812
- Testing
- SHR-1819 injection
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Moderate-to-severe Atopic Dermatitis
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07344051
- Testing
- QLS12010
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Trial name
- NCT05984784
- Testing
- IMG-007
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Inmagene LLC
Moderate to Severe Atopic Dermatitis
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic…
- Trial name
- NCT06239311
- Testing
- Methotrexate
- Where
- 30 sites in Czechia, France and 2 more
- Volunteers
- 277 people
- Sponsor
- medac GmbH
Moderate-to-severe Atopic Dermatitis
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06158490
- Testing
- JYP0061 15 mg, JYP0061 30 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Moderate-to-severe Atopic Dermatitis
The Study of CM310 in Patients With Atopic Dermatitis
This is an open, multicenter, extension study evaluating the safety and efficacy of CM310 for long-term treatment in patients with atopic dermatitis The primary objective is to assess the long-term safety of CM310 administered in…
- Trial name
- NCT04893707
- Testing
- CM310
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Keymed Biosciences Co.Ltd
Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03985943
- Testing
- Nemolizumab
- Where
- 174 sites in United States, Australia and 12 more
- Volunteers
- 941 people
- Sponsor
- Galderma R&D
Moderate-to-Severe Atopic Dermatitis
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03989349
- Testing
- Nemolizumab
- Where
- 138 sites in United States, Belgium and 9 more
- Volunteers
- 787 people
- Sponsor
- Galderma R&D
Moderate to Severe Atopic Dermatitis
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
- Trial name
- NCT05997927
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT05017480
- Testing
- CBP-201
- Where
- 48 sites in China
- Volunteers
- 330 people
- Sponsor
- Connect Biopharm LLC
Moderate to Severe Atopic Hand and Foot Dermatitis
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis.
- Trial name
- NCT04417894
- Testing
- dupilumab
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 133 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate-to-severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
The primary objective of this study is to investigate the efficacy of nemolizumab administered in combination with topical background therapy (topical corticosteroids [TCS] with or without topical calcineurin inhibitors [TCI]) in…
- Trial name
- NCT05056779
- Testing
- Nemolizumab
- Sponsor
- Galderma R&D
Moderate-to-severe Atopic Dermatitis
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Primary Objective: Part A To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score To determine the entry criterion…
- Trial name
- NEURADAD (NCT05203380)
- Testing
- dupilumab
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate-to-severe Atopic Dermatitis
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT04444752
- Testing
- CBP-201
- Where
- 59 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Connect Biopharm LLC
Moderate to Severe Atopic Dermatitis
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
The investigator, the subject, and the sponsor's project team will remain blind throughout the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio of 1:1:1 to be given the drug once a day for…
- Trial name
- NCT05702268
- Testing
- ICP-332
- Where
- 28 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.
- Trial name
- NCT05671432
- Testing
- CM326
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Keymed Biosciences Co.Ltd